Press Release, San Antonio, TX / October 17, 2019 / Rochal Industries LLC.
Based in San Antonio, Texas, Rochal Industries LLC., a global leader in commercializing technology innovations in natural and synthetic polymers, antimicrobials, and biological systems, announced that Dr. Rebecca McMahon has been named President of the company. Ann Beal Salamone, Rochal’s past-President and Co-Founder has been elected as Chairman of the Board. Ron Nixon, the previous Chairman of the Board and the Founder and Managing Partner of the Catalyst group, will step down as Chairman but remain on the Board of Directors.
Outgoing President Ann Beal Salamone praised Dr. McMahon as the right choice to build on her and her husband’s (Rochal Co-Founder Dr. Joseph C. Salamone) legacy of innovation. “Rebecca is a leader with a deep understanding of medical device innovation and product development. With her strong academic background and years of experience with the company, she has the technical and business skills to take Rochal into the future.”
Dr. McMahon has been with Rochal Industries since 2015. She has held a variety of research and development positions within the company including most recently the Wound Therapeutics Director. Prior to Rochal, Dr. McMahon was a Postdoctoral Fellow at MD Anderson Cancer Center in Houston, TX. Dr. McMahon received a Ph.D. in Chemical Engineering from Texas A&M University, a Master of Business Administration from The University of Texas at San Antonio, and a dual Bachelor of Science Degree in Chemical Engineering and Science, Technology, and Society from Rennsselaer Polytechnic Institute.
“Rochal has found the right leader in Rebecca to take the reins from Ann and build on the strong foundation she and her husband created,” stated outgoing Chairman Ron Nixon. He added, “With Ann taking over as Chairman of the Board and Rebecca being named President, Rochal is well positioned to continue its successful track record of product innovation and commercialization.”
Rochal Industries is a global leader in commercializing technology innovations in natural and synthetic polymers, antimicrobials, and biological systems. As a research-oriented company focused on wound and skin care, Rochal created the field of non-stinging liquid bandages in the 1990’s. The company’s current pipeline contains transformative products for mitigation of opportunistic pathogens and biofilm, wound re-epithelialization and closure, necrotic tissue debridement, cell compatible substrates and transdermal drug delivery. Rochal drives its pipeline from concept to preclinical and clinical development through product validation, FDA clearance and lifecycle management, while retaining its core competency in scientific innovation.